AMERICAN INTERNATIONAL GROUP, INC. - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
AMERICAN INTERNATIONAL GROUP, INC. ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$959,115
+107.4%
32,250
+25.7%
0.01%
+100.0%
Q2 2023$462,483
+13.4%
25,665
+1.0%
0.00%0.0%
Q1 2023$407,908
-10.5%
25,399
+2.0%
0.00%0.0%
Q4 2022$455,542
-7.2%
24,893
-0.4%
0.00%
-25.0%
Q3 2022$491,000
+7.0%
24,984
+1.4%
0.00%
+33.3%
Q2 2022$459,000
-8.6%
24,630
+7.6%
0.00%0.0%
Q1 2022$502,000
-27.9%
22,881
-6.6%
0.00%0.0%
Q4 2021$696,000
+61.5%
24,492
+19.6%
0.00%
+50.0%
Q3 2021$431,000
+11.9%
20,479
+0.2%
0.00%
+100.0%
Q2 2021$385,000
+59.8%
20,439
+29.6%
0.00%0.0%
Q1 2021$241,000
+8.6%
15,771
+0.3%
0.00%0.0%
Q4 2020$222,000
-12.6%
15,730
-2.8%
0.00%0.0%
Q3 2020$254,000
-12.4%
16,181
-2.2%
0.00%0.0%
Q2 2020$290,000
+202.1%
16,549
+153.2%
0.00%0.0%
Q1 2020$96,000
-44.5%
6,537
-5.5%
0.00%0.0%
Q4 2019$173,000
+64.8%
6,914
-0.8%
0.00%
Q3 2019$105,000
-40.3%
6,972
-0.7%
0.00%
-100.0%
Q2 2019$176,000
+40.8%
7,022
+28.2%
0.00%
Q1 2019$125,000
-9.4%
5,478
+19.5%
0.00%
-100.0%
Q4 2018$138,000
+4.5%
4,585
-0.8%
0.00%
Q3 2018$132,0004,6200.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q3 2021
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,030,616$31,028,0006.04%
5AM Venture Management, LLC 1,362,286$20,816,0003.75%
Burrage Capital Management LLC 272,393$4,162,0003.37%
Altium Capital Management LP 361,930$5,530,0001.54%
Vivo Capital, LLC 2,214,138$33,832,0001.19%
Bain Capital Life Sciences Investors, LLC 1,071,428$16,371,0000.93%
Perceptive Advisors 3,659,381$51,606,0000.65%
New Leaf Venture Partners, L.L.C. 141,000$2,154,0000.50%
DRIEHAUS CAPITAL MANAGEMENT LLC 2,003,688$30,616,0000.45%
Opaleye Management Inc. 188,000$2,873,0000.42%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders